AF
TCRT icon

Amalgamated Financial’s Alaunos Therapeutics TCRT Stock Holding History

Amalgamated Financial’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$22K Buy
+228
New +$29.3K ﹤0.01% 2722

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Amalgamated Financial's TCRT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Alaunos Therapeutics (TCRT) in Q1 2022: 228 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #2722 among its holdings.

148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • Amalgamated Financial held 228 shares of Alaunos Therapeutics worth $22K as of Q1 2022.
  • Alaunos Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Alaunos Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2722 holding.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.